Grüns Acquisition, Valuation, Funding & Investors

Grüns was acquired by Unilever for $1.2B in April 2026, a 4.0x multiple on $300M of revenue.

Grüns acquisition price

$1.2B

Acquired by Unilever · Apr 2026

Grüns revenue at acquisition

$300M

Last twelve months · Apr 2026

Grüns revenue multiple at acquisition

4.0x

EV/Revenue · Apr 2026

Cumulative funding Grüns raised

$10M

across 1 funding round

Grüns Overview

About Grüns

Grüns is a company producing health supplements as gummy snacks. It formulates nutrition products with vitamins, probiotics, and superfoods targeted at daily wellness for adults and children.


Founded

2023

HQ

United StatesPortland, OR

Website

gruns.co

Status

Acquired

Customer focus

B2C

Revenue model

Product sales

Revenue

$300M (Apr 2026)

Valuation

$450M (Apr 2025)

Grüns Acquisition

Grüns was acquired by Unilever for $1.2B on 8 April 2026.

The acquisition price implies a 4.0x revenue multiple on $300M of revenue.

Before the acquisition Grüns had raised $10M across 1 funding round.

Grüns acquisition details
AcquirerDateTypePriceEV/Revenue
8 Apr 2026Strategic M&A$1.2B4.0x

Grüns Valuation

Grüns is currently valued at $450M, based on its undisclosed-stage round in April 2025.

Grüns valuation by funding round

Grüns valuation by funding round
DateStageValuation
Apr 2025Undisclosed stage$450M

Grüns Funding History

Grüns has raised a total of $10M across 1 funding round.

Grüns funding rounds

Grüns funding rounds
DateStageRaisedValuationDeal Summary
Apr 2025Undisclosed stage$10M$450MGrüns is a gummy supplement company offering functional gummy bears with ingredients like powdered fruits and vegetables, vitamins, probiotics, and nootropics for nutritional support, including kids' versions and cognitive products. The company launched in 2023, sells DTC and in over 5,000 retail doors including Sprouts, Target, and Walmart, and ships 4 million gummies per day. It has expanded product lines with new SKUs and plans international growth into Asia and Australia. In April-May 2025, Grüns raised $35 million in a Series B round led by Headline, with participation from Plus Capital, Sugar Capital, and celebrities like Anna Kendrick and Shaun White, achieving a post-money valuation of $500 million USD. This followed prior funding including $18 million in 2024 and brought total funding to over $50 million across multiple rounds. The capital supports scaling distribution, launching new products like one per quarter starting August 2025, retail expansion, TV advertising, sports partnerships such as with Gotham FC, and international markets. Grüns demonstrated strong traction with nine-figure annual recurring revenue at the time of the Series B, rapid retail penetration in major chains within two years, and appeal to Gen Z and millennials preferring gummies over pills for needs like gut health, energy, and immunity. The brand positions in the growing gummy supplement market, which comprises 23% of supplement sales, amid a boom in supplement startups.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Grüns Competitors

Grüns competitors include listed companies like Jamieson Wellness, Procter & Gamble Health, Mega Lifesciences and Zydus Wellness, and private ones like L&P Cosmetic and Grupo Cimed.

Public and private companies comparable to Grüns
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Jamieson WellnessCanadaCanadaPublicly listed$589M$95M$1.4B2.6x
Procter & Gamble HealthIndiaIndiaPublicly listed$144M$48M$941M6.0x
Mega LifesciencesThailandThailandPublicly listed$425M$82M$936M1.9x
Zydus WellnessIndiaIndiaPublicly listed$411M$49M$1.8B4.5x
L&P CosmeticSouth KoreaSeoulPrivate--$1.1B-
Grupo CimedBrazilSão PauloPrivate--$1.4B-

Grüns Public Comps

Grüns is no longer listed, but its public comps include Edgewell, BioGaia, Chicmax Cosmetic, Jamieson Wellness, Intercos, Cosmecca Korea, Procter & Gamble Health, Mega Lifesciences, T Hasegawa and Sarantis Group.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Edgewell$2.2B$186M1.0x1.1x11.5x8.5x
BioGaia$157M$44M6.8x6.2x23.9x20.4x
Chicmax Cosmetic$1.4B$235M0.8x0.8x4.5x7.3x
Jamieson Wellness$589M$95M2.9x2.6x17.8x13.5x
Intercos$1.2B$159M1.2x1.2x9.4x8.0x
Cosmecca Korea$467M$71M2.5x2.1x16.5x12.9x
Procter & Gamble Health$144M$48M6.4x6.0x19.1x18.3x
Mega Lifesciences$425M$82M2.0x1.9x10.2x8.4x

This data is available for Pro users. Sign up to see all Grüns competitors and their valuation data.

Start Free Trial

Common questions about Grüns

When was Grüns founded?Grüns was founded in 2023.
Where is Grüns headquartered?Grüns is headquartered in Portland, OR, United States.
Is Grüns publicly listed?No, Grüns was acquired by Unilever in April 2026.
Who acquired Grüns?Grüns was acquired by Unilever in April 2026.
How much was Grüns acquired for?Grüns was acquired for $1.2B in April 2026, a 4.0x revenue multiple.
What is Grüns' valuation?Grüns was last valued at $450M in its undisclosed-stage round in April 2025.
How much funding has Grüns raised?Grüns has raised $10M across 1 funding round.
What was Grüns' last funding round?Grüns' last funding round was a $10M undisclosed-stage round in April 2025.
Which companies are comparable to Grüns?Companies comparable to Grüns include Jamieson Wellness, Procter & Gamble Health, Mega Lifesciences, Zydus Wellness, L&P Cosmetic and Grupo Cimed.

See companies similar to Grüns

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial